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The compounds 1-benzyl-2-imino-4-p-tolyl-
1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-
carbonitrile (Ia)  and 1-benzyl-2-imino-(4-
methoxyphenyl-1,2,5,6,7,8,9,10-octahydrocycloocta 
{b]pyridine-3-carbonitrile (Ib) were synthesized. The 
crystal structures of the compounds were determined 
by single crystal X ray diffraction. The compounds C26 
H27 N3 (Ia)  and  C26 H27 N3O  (Ib)  crystallize in the 
triclinic system (a = 10.2304(4) Å, b = 10.5655(4) Å, c 
= 11.8271(4) Å, α = 101.755(2) °, β = 106.934(2) °, γ 
= 114.071(2) ° and Z = 2  for I(a) and a = 10.2738(4) 
Å, b = 11.1654(5) Å, c = 11.4162(4) Å α = 98.549(2) 
°, β = 106.183(2) °, γ = 117.070(2) ° and Z = 2 for I
(b)). In both compounds (Ia) and (Ib) the pyridine ring 
adopts a planar conformation and the cyclooctane ring 
adopts a twisted boat chair conformation. The synthe-
sized compounds were screened for  their  antibacterial 
activities against the enzyme enoyl acyl carrier protein 
reductase, which is involved in the fatty acid biosyn-
thesis of the mycobacterial cell wall. Both compounds 
showed good antibacterial activities. The synthesis of 
the compounds, their structure determination, their 
conformation, their intra- and intermolecular interac-
tions and docking study results are given. 
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Introduction 
 
Tuberculosis (TB) is an infectious disease caused by 
Mycobacterium tuberculosis and is the second leading 
cause of death in developing countries. Primary infec-
tion of M. tuberculosis takes place within the lungs but 
can involve any organ (Dietrich & Doherty 2009). 
Multidrug resistant tuberculosis and extensively drug-
resistant tuberculosis have highlighted the deficiency 
of current standard treatment regimens. The bacterial 
drug resistance is mainly due to the slow growth, un-
usual cell envelope and genetic homogeneity (Besra et 
al. 1994). The cell wall of M. tuberculosis contains 
certain unique long chain (C70 to C90), α-alkyl and β-
hydroxy fatty acids, referred to as mycolic acids. Its 
unusual lipid bilayer, formed by the latter, together 
with glycolipids and lipoprotein makes the cell wall 
tough, and the drugs normally used for the treatment of 
the infection, partially effective (Pieters 2008). Hence, 
there is a need to develop new drug candidates which 
have anti-mycobacterial activity.  
 The heterocycles containing nitrogen show 
good anti-mycobacterial activities (Sriram et al. 2006).  
Many naturally occurring and synthetic compounds 
containing the pyridine scaffold show important phar-
macological properties (Temple et al. 1992). Cyano-
pyridine derivatives possess anti-microbial activities 
(Dandia et al. 1993). As a continuation of our work for 
developing new drugs for M. tuberculosis (Suresh et 
al. 2012), the 1-benzyl-2-imino-4-p-tolyl-
1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-
carbonitrile (Ia)  and 1-benzyl-2-imino-(4-
methoxyphenyl-1,2,5,6,7,8,9,10-octahydrocycloocta[b]
pyridine-3-carbonitrile (Ib) compounds were synthe-
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Figure 1. Chemical diagram of the molecule (Ia) (left) and 
(Ib) (right).  
sized and their structural characteristics were studied 
using single crystal X-ray diffraction. Furthermore, 
they were screened for anti-mycobacterial activities 
using Autodock. 
 
Synthesis 
 
Preparation of compound (Ia) 
A mixture of cyclooctanone (1 mmol), 4-methyl ben-
zaldehyde (1 mmol) and malononitrile (1 mmol) were 
taken in ethanol (10 mL); pTSA (0.5 mmol) was sub-
sequently added. The reaction mixture was heated un-
der reflux for 2-3 h. After completion of the reaction 
(TLC), the reaction mixture was poured into crushed 
ice and extracted with ethyl acetate. The excess solvent 
was removed under vacuum and the residue was sub-
jected to column chromatography using petroleum 
ether/ethyl acetate mixture (97:3 v/v) as eluent to af-
ford pure product. The pure product was crystallized 
using ethyl acetate, as solvent. The melting point was 
501 K and the yield was 69%. 
 
Preparation of compound (Ib) 
A mixture of cyclooctanone (1 mmol), 4-methoxy ben-
zaldehyde (1 mmol) and malononitrile (1 mmol) were 
taken in ethanol (10 mL); pTSA (0.5 mmol) was sub-
sequently added. The reaction mixture was heated un-
der reflux for 2-3 h. After completion of the reaction 
(TLC), the reaction mixture was poured into crushed 
ice and extracted with ethyl acetate. The excess solvent 
was removed under vacuum and the residue was sub-
jected to column chromatography using petroleum 
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Table 1. The crystal data, intensity data collection, structure solution and structure refinement parameters of compounds (Ia) 
and (Ib). 
Empirical formula C26 H27 N3 C26 H27 N3 O 
Formula weight 381.51 397.51 
Temperature 293(2) K 293(2) K 
Wavelength 0.71073 Å 0.71073 Å 
Crystal system /space group Triclinic/P-1 Triclinic/ P-1 
Unit cell dimensions 
a = 10.2304(4) Å a = 10.2738(4) Å 
b = 10.5655(4) Å b = 11.1654(5) Å 
c = 11.8271(4) Å c = 11.4162(4) Å 
a = 101.755(2)° a = 98.549(2)° 
b = 106.934(2)° b = 106.183(2)° 
g  = 114.071(2)° g = 117.070(2)° 
Volume 1037.69(7) Å3 1060.20(7) Å3 
Z/ Density (calculated) 2/ 1.221 Mg/m3 2/1.245 Mg/m3 
Absorption coefficient 0.072 mm-1 0.077 mm-1 
F(000) 408 424 
Crystal size 0.21x0.19 x0.18 mm3 0.21 x 0.19 x 0.18 mm3 
Theta range for data collection 2.27 to 25.50°. 2.16 to 25.49°. 
Limiting indices 
-12<=h<=12, 
-12<=k<=12, 
-14<=l<=14 
-12<=h<=12, 
-13<=k<=13, 
-13<=l<=13 
Reflections collected 23565 25081 
Independent reflections 3865 [R(int) = 0.0272] 3947 [R(int) = 0.0302] 
Completeness to theta = 25.50° 100.0 % 99.9 % 
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 
Data / restraints / parameters 3865 / 2 / 268 3947 / 16 / 311 
Goodness-of-fit on F2 1.052 1.035 
Final R indices [I>2sigma(I)] 
R1 = 0.0453, 
wR2 = 0.1175 
R1 = 0.0474, 
wR2 = 0.1258 
R indices (all data) 
R1 = 0.0710, 
wR2 = 0.1335 
R1 = 0.0761, 
wR2 = 0.1463 
Extinction coefficient 0.020(3) 0.034(4) 
Largest diff. peak and hole 0.275 and -0.177 e.Å-3 0.197 and -0.238 e.Å-3 
ether/ ethyl acetate mixture (97:3 v/v) as eluent to af-
ford pure product. The pure product was crystallized 
using ethyl acetate, as solvent. The melting point was 
511 K and the yield was 70%. 
 
Structure Determination and Refinement 
 
Single crystals of suitable sizes of both compounds 
were selected for crystal structure determination. The 
intensity data of the crystals were collected using a 
Bruker AXS Kappa APEX II single crystal CCD Dif-
fractometer equipped with graphite-monochromated 
MoKα radiation (λ=0.71073Å) at room temperature. 
The data collection, data reduction and absorption cor-
rections were carried out using the APEX2, SAINT-
Plus and SADABS programs (Bruker 2004). The trial 
structures of both the compounds were obtained  using 
SHELXL-97. The structures were refined by the full-
matrix least-squares method using SHELXL-97 
(Sheldrick 2008). The non-hydrogen atoms were also 
refined with independent anisotropic displacement pa-
rameters using the same program (Sheldrick 2008). 
The NH hydrogen atoms were located from a differ-
ence Fourier map and refined isotropically. The other 
H atoms were placed in calculated positions and al-
lowed to ride on their carrier atoms with C---H = 0.93 
Å (aromatic CH), 0.96 Å (methyl CH3) or 0.97 Å 
(methylene CH2), and N---H = 0.86 Å. Isotropic dis-
placement parameters for H atoms were calculated as 
Uiso = 1.5Ueq(C) for CH3 groups and Uiso = 1.2Ueq 
(carrier atom) for all other H atoms. The methoxy sub-
stituted molecule was disordered. The carbon atoms 
C8 and C9, with their corresponding hydrogen atoms 
of the cyclooctane ring of the compound (Ib) are disor-
dered with occupancy factors 0.33485:0.60186, re-
spectively. The disordered carbon atoms of the 
cyclooctane ring were refined using SHELXL-97 
(Sheldrick 2008).  
 
Docking Studies 
 
Isoniazid (INH) was initially found to be active against 
tuberculosis in 1952, while its mode of action was still 
unknown (Bernstein et al. 1952, Fox 1952). It was 
later shown that INH inhibits the biosynthesis of my-
colic acid, that covers the surface of mycobacteria 
(Takayama et al. 1972). There is strong evidence that 
this is the pathway that exerts the main effect of INH 
treatment (Winder 1982, Quemard et al. 1991). Using 
gene transfer systems for mycobacteria, a gene called 
InhA was identified as a target for INH (Banerjee et al. 
1994). These studies revealed that InhA preferentially 
catalyzes the NADH-dependent reduction of 2-trans-
enoyl-ACP molecules with 16 or more carbons 
(Dessen et al. 1995, Quemard et al. 1995). This serves 
as the last step in fatty acid elongation. Despite the 
increasing numbers of primary and secondary resis-
tance, isoniazid remains one of the key drugs to treat 
tuberculosis (Cohn et al. 1997).  Further studies show 
that INH can penetrate the mycobacterial envelope 
through passive diffusion; it then inhibits the InhA en-
zyme by covalently attaching to NADH within the pro-
tein active site  (Rozwarski et al. 1998). Additionally, 
inhibition of InhA blocks mycolic acid biosynthesis, 
eventually leading to cell death (Vilcheze et al. 2000). 
The enoyl-acyl carrier protein reductase from Myco-
bacterium tuberculosis (InhA) is a fundamental target 
for antituberculosis intervention (Dessen et al. 1995, 
Rozwarski et al. 1998). 
 Nowadays, even though the antibacterial ef-
fects of isoniazid and triclosan (a newer InhA inhibi-
tor) establish the suitability of the target for drug inter-
vention, these compounds themselves have several 
limitations, including resistance and suboptimal 
bioavailability (Wang et al. 2004). Here, we report a 
new chemically distinct series, 1-benzyl-2-imino-4-(4-
methylphenyl)-1, 2,5,6,7,8,9,10-octahydrocycloocta[b]
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Figure 2. The molecular structure of compounds (Ia) (left) and (Ib) (right), showing the atom numbering scheme. Displacement 
ellipsoids are drawn at 20% probability level, using Platon (Spek 2008).  
 
pyridine-3-carbonitrile, which has anti-mycobacterial 
activity. We have attempted, aided by a docking ap-
proach, to elucidate the extent of specificity of enoyl 
acyl carrier protein towards synthesized compounds, as 
anti-tubercular agents. The coordinates of enoyl acyl 
carrier protein (2NSD) with Nad were then retrieved 
from the RCSB protein data bank (http://
www.pdb.org). The protein structure was cleaned us-
ing the whatif online server. Enoyl acyl carrier pro-
tein’s active site pocket was identified using the online 
server Computed Atlas of Surface Topography 
(CASTp). The preparation of the protein and ligand 
input structures and the definition of the binding sites 
were carried out under a GRID-based procedure. A 
rectangular grid box was constructed over the protein 
with grid points 90X90X90 Å3 separated by 0.375 Å 
under the docking procedure. The lowest energy clus-
ter returned by AutoDock for each compound was con-
sidered and used for further analysis. Consequently 
runs were setup to 100 for each inhibitor. All other 
parameters were maintained at their default settings. 
All docking result visualizations are depicted using the 
PDBsum online server. 
 
Results and Discussion 
 
The molecular structures of compounds (Ia) and (Ib) 
are shown in Figure 2. In both compounds, the 
cyclooctane ring adopts a twisted boat-chair conforma-
tion. The pyridine ring is planar with an r.m.s. devia-
tion of 0.0041 (1) Å in (Ia) and 0.0085 (1)  Å in (Ib). 
The N1 atom is deviating by -0.0446 (1) Å from the 
mean plane of the pyridine ring in compound (Ia) and 
0.393 (1) Å in compound (Ib). The aromatic ring (C31-
C36) and phenyl rings (C13-C18) are planar with an 
r.m.s. deviation of 0.0059 Å and 0.0070 Å in com-
pound (Ia) and in compound (Ib). The sum of the an-
gles around atom N3 (360◦) indicates that the atom N3 
is in sp2 hybridization in both compounds. The nitrile 
atoms C38 and N2 are displaced from the mean plane 
of the pyridine ring by 0.0384(1) Å and 0.0612(1) Å, 
respectively, in compound (Ia) and -0.0090(1) Å and 
0.0050(1) Å, in compound (Ib). The methyl benzene 
ring attached to the pyridine ring is in an (-) anti-clinal 
conformation with torsion angle C2--C3--C31--C36 = 
-98.5(2) ◦ in compound (Ia) and in an (+) anti-clinal 
conformation with torsion angle C2--C3--C31--C36 = 
99.8(2) ◦ in compound (Ib). The torsion angle C32--
C34--C33--C37 = -179.3◦ (2) indicates the methyl car-
bon atom attached to the benzene ring is in an (-) anti 
peri planar conformation in compound (Ia). The plane 
formed by the cyano group is twisted away from the 
plane of pyridine ring in both compounds; 50.42 ( 1 )◦   
in compound (Ia) and 36.20 ( 1 )◦  in compound (Ib). 
 
Crystal Packing  
 
In the crystal structure of the compound (Ia) the atom 
C32 of the aryl ring is involved in the intermolecular 
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Figure 4. Enoyl acyl carrier protein reductase interactions 
for compound (Ia). 
Figure 3. The inversely related molecules form a ring motif; they are further linked through C-H…π (left) and van der walls 
(right) interactions in the case of compound (Ia) (left) and (Ib) (right). 
interaction C32—H32···N1(i) (with the N1 atom) and 
forms a ring motif R2
2(14) (Bernstein et al. 1995) 
along the b axis [symmetry code: (i) (- x, - y, 1 – z)]. 
These adjacent ring motifs are linked together by C-
H…π (ii) interactions [symmetry code: (ii) (1 - x, 1 - y, 
1 – z)], (Figure 3). Furthermore, in the crystal structure 
of compound (Ib) the intermolecular interaction C32—
H32···N1(i) with the N1 atom forms a ring motif R2
2
(14) (Bernstein et al. 1995) along the b-axis  
[symmetry code: (i) (1 - x, 1 - y, 1 – z)]. These adja-
cent ring motifs are linked together by van der Walls 
interactions (Figure 3).  
 The C—N distance is longer [3.473 (3) Å] in 
compound (Ia) than in compound (Ib) [3.465 (3) Å]  
even though the C—H···N angle [154 (2) ◦, 154 (17) ◦] 
is similar in both structures. This shows that the 4-
methoxy substituent forms a stronger hydrogen bond 
than the methyl substituent. The intermolecular hydro-
gen bond geometry of compound (Ia) and compound 
(Ib) is listed in Table 2. 
 
Docking analysis 
 
The target protein structure of 2NSD with Nad was 
docked with the synthesized compounds using Auto-
Dock4 version 2 (Goodsell 1998). The target protein 
contains two monomers. Only one monomer was se-
lected for docking studies (Figure 4).  
 The synthesized compounds were found 
to display good binding affinity to the receptor 
as shown in Table 3 and in Figure 6, with mini-
mum binding energy. From Table 4, it was 
found that the stabilized binding interactions of 
our compounds are due the strong influence 
from the VDW + Hbond + desolv energy, than 
the electrostatic interactions. 
 The hydrophobic pocket of InhA is 
flexible whereas its hydrophilic pocket appears 
more rigid for the binding of inhibitors (Punkvang 
et al. 2010). InhA inhibitors may interact with its 
hydrophilic pocket formed by the backbone of Gly 
96, Phe 97 and Met 98. Hydrophobicity is favourable for 
the MIC value but its appears to be unfavorable for the 
activity against M. tuberculosis. Hence, there should 
be a fine balance between the hydrophobic and hydro-
philic properties of direct InhA inhibitors, to ensure 
their effectiveness against both InhA and M. tubercu-
losis. These structural requirements are favorable not 
only for MIC values but also assist the binding of InhA 
inhibitors in the hydrophilic InhA pocket. The key 
structural feature of such InhA inhibitors should be 
taken. Thus, having a bulky group encompassing suit-
able hydrophobic and hydrophilic properties could im-
prove the MIC value of direct InhA inhibitors. 
 In compound (Ia), the nitrogen atom of the 
pyridine ring is hydrogen bonded to GLY 96, one of the 
catalytic residues in the InhA active site. The hydrogen 
bond is formed in the hydrophilic pocket and has hy-
drophobic interactions with the hydrophobic pocket. 
Hence it shows good anti-mycobacterial activity. 
 Rozwarski et al. (1999) determined the crystal 
structure of InhA with a C fatty acyl substrate; they 
reported that hydrophobic amino acids of the loop are 
important for substrate binding into the cavity. Of 
note, the last few carbon atoms of the substrate were 
shown to interact with Ala198, Met199, and Ile202, which 
are all hydrophobic. A fatty acid shorter than 16 car-
bons might not fit well in the enzyme, as there will be 
missing interactions with Ala198, Met 199, and Ile202. 
There is strong evidence that the interac-
tions with the three amino acids are im-
portant determinants for loop ordering. 
Our inhibitor (Ib) is able to directly inter-
act with one of these residues (Ala198), 
generating a defined loop structure and 
having hydrophobic interactions to the 
important loop residues of  InhA, leading 
to a slow tight binding inhibition. Inhibi-
tor residence time is an important factor 
for in vivo drug activity (Lavie et al. 1997, 
Lewandowicz et al. 2003, Tummino et al. 
2008). Slow onset inhibitors will spend a 
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Table 3. Hydrogen bonds [Å and °] of compound (Ib)   
 Symmetry transformation used to generate equivalent atoms: 
(i)   (1 - x, 1 - y, -z) 
D-HA d(D-H) ...d(HA) ...d(DA) <DHA 
C(32)-H(32)...N(1)(i) 0.93 2.61 3.473(2) 154 
C(11)-H(11)...Cg1(ii) 0.97 2.93 3.583(2) 126 
D-HA d(D-H) ...d(HA) ...d(DA) <DHA 
C(18)-H(18)...N(1) 0.93 2.61 3.284(3) 130 
C(32)-H(32)...N(1)(i) 0.93 2.60 3.464(3) 154 
Table 2. Hydrogen bonds [Å and °] of compound (Ia). Cg1 is the 
centroid of the (C13-C18) phenyl ring. 
Symmetry transformations used to generate equivalent atoms: 
(i)   (- x, - y, 1 – z) 
(ii)   (1 - x,1 - y,1 – z) 
 
longer time bound to their target molecules and can 
remain bound even at low free drug concentrations. In 
this regard, our inhibitor (Ib) shows the features of 
slow onset inhibitors. 
 
Conclusion 
 
For our goal to propose new inhibitors, we synthesized 
two compounds of pyridine derivatives. The com-
pounds were docked and their binding free binding 
energies were evaluated. Both compounds show good 
binding affinity with acceptable free binding energy 
which indicates that they give good stable complexes. 
Hence our synthesized ligands show good antitubercu-
lar activities. From the docking analysis of the two 
compounds with the receptor of enoyl acyl carrier pro-
tein it was found that (Ib) shows better binding with 
the receptor, as compared to (Ia). 
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Ligand 
Binding Energy
(Kcal/mol) 
Intermolecular En-
ergy (Kcal/ mol) 
(A+B) 
VDW + Hbond + 
desolv energy (Kcal/
mol) 
(A) 
Electrostatic energy
(Kcal/ mol) (B) 
Ia -7.83 -9.03 -9.02 -0.01 
Ib -8.67 -10.16 -9.93 -0.23 
Table 4. Binding energy of compounds (Ia) and (Ib). 
Figure 5. Interactions of compound (Ia) (left) and compound (Ib) (right) with enoyl acyl carrier protein. 
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